Focused On-demand Library for Ketimine reductase mu-crystallin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14894

UPID:

CRYM_HUMAN

Alternative names:

NADP-regulated thyroid-hormone-binding protein

Alternative UPACC:

Q14894; D5MNX0; Q5HYB7

Background:

Ketimine reductase mu-crystallin, also known as NADP-regulated thyroid-hormone-binding protein, plays a crucial role in the brain's chemical processes. It specifically catalyzes the reduction of imine bonds in substrates like cystathionine ketimine and lanthionine ketimine. Additionally, it interacts with thyroid hormone, acting as a potent reversible inhibitor, which suggests its involvement in regulating triiodothyronine's intracellular concentration and its nuclear receptor access.

Therapeutic significance:

The protein's association with Deafness, autosomal dominant, 40, underscores its clinical relevance. This condition, characterized by non-syndromic sensorineural hearing loss, is linked to variants affecting the gene encoding this protein. Understanding the role of Ketimine reductase mu-crystallin could open doors to potential therapeutic strategies for hearing loss and related neurological conditions.